Astrazeneca will invest $ 2.5 billion in Beijing Hub

Astrazeneca On Friday, in the central investment and development center in the Chinese capital, the capital of China, because the British pharmaceutical giant, because the British pharmaceutical giant, wanted to be transformed from Chinese probes.

The new center is expected to receive Astrazeneca’s Beijing workforce for about 1,700 employees.

Beijing comes as part of a partnership with the administrative office of the mayor of the Ministry of Economic Development of the Investment City and Beijing.

Under the transaction, Astrazeneca Biotech firms will include research and development employees with Harbor Biomed and Syneron Bio and will launch a joint venture with biokangtai for market vaccinations.

Partnership with BioKangtai will see that the company opened the first vaccination production enterprise in China.

AstraRazeneca’s Beijing Research Center will be second in China, the company will be the second place in the Shanghai Research and Development Center. Beijing Center “will partner with the most advanced biology and AI science in Beijing and will be a critical part of our global efforts to bring innovative drugs to patients in the world,” he said.

Astrazeneca shares fell to 1% at 11:13 o’clock in London.

The company has been reported to be in China Full annual earnings report in February.

“The best of the knowledge of Astrazeneca’s knowledge, import taxes (cancer drugs) Imfinzi and Imjudo associated with Import Taxes”, then said. “If Astrazeneca is brought to a prosecution, the amount of unpaid taxes may be charged. AstraZeneca continues to cooperate with the Chinese government.

Soriot said in a statement on Friday, Astrazeneca of $ 2.5 billion in investment in Beijing has shown a “sustainable commitment to China.”

This broke news story is updated.